Cigna Corporation (CI) Stock Competitors & Peer Comparison
See (CI) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CI | $295.72 | +2.11% | 78B | 2.59 | $113.71 | +2.09% |
| UNH | $408.40 | +0.45% | 374.8B | 31.06 | $13.29 | +2.15% |
| CVS | $97.22 | +0.14% | 123.8B | 42.56 | $2.28 | +2.74% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| ELV | $408.43 | -2.32% | 92.2B | 17.99 | $23.60 | +1.61% |
| HUM | $365.72 | +2.74% | 43.6B | 38.79 | $9.36 | +0.97% |
| CNC | $64.38 | -1.00% | 32.7B | -5.07 | -$13.05 | N/A |
| MOH | $197.97 | -0.22% | 10.6B | 54.58 | $3.72 | N/A |
| OSCR | $28.27 | +3.21% | 7.1B | -50.41 | -$0.54 | N/A |
| ALHC | $20.49 | +33.45% | 4B | 192.00 | $0.10 | N/A |
Stock Comparison
CI vs UNH Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, UNH has a market cap of 374.8B. Regarding current trading prices, CI is priced at $295.72, while UNH trades at $408.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas UNH's P/E ratio is 31.06. In terms of profitability, CI's ROE is +0.15%, compared to UNH's ROE of +0.12%. Regarding short-term risk, CI is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check UNH's competition here
CI vs CVS Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, CVS has a market cap of 123.8B. Regarding current trading prices, CI is priced at $295.72, while CVS trades at $97.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas CVS's P/E ratio is 42.56. In terms of profitability, CI's ROE is +0.15%, compared to CVS's ROE of +0.04%. Regarding short-term risk, CI is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check CVS's competition here
CI vs ANTM Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, CI is priced at $295.72, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas ANTM's P/E ratio is 18.99. In terms of profitability, CI's ROE is +0.15%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, CI is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ANTM's competition here
CI vs ELV Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, ELV has a market cap of 92.2B. Regarding current trading prices, CI is priced at $295.72, while ELV trades at $408.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas ELV's P/E ratio is 17.99. In terms of profitability, CI's ROE is +0.15%, compared to ELV's ROE of +0.12%. Regarding short-term risk, CI is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ELV's competition here
CI vs HUM Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, HUM has a market cap of 43.6B. Regarding current trading prices, CI is priced at $295.72, while HUM trades at $365.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas HUM's P/E ratio is 38.79. In terms of profitability, CI's ROE is +0.15%, compared to HUM's ROE of +0.06%. Regarding short-term risk, CI is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check HUM's competition here
CI vs CNC Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, CNC has a market cap of 32.7B. Regarding current trading prices, CI is priced at $295.72, while CNC trades at $64.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas CNC's P/E ratio is -5.07. In terms of profitability, CI's ROE is +0.15%, compared to CNC's ROE of -0.29%. Regarding short-term risk, CI is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CNC's competition here
CI vs MOH Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, MOH has a market cap of 10.6B. Regarding current trading prices, CI is priced at $295.72, while MOH trades at $197.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas MOH's P/E ratio is 54.58. In terms of profitability, CI's ROE is +0.15%, compared to MOH's ROE of +0.04%. Regarding short-term risk, CI is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check MOH's competition here
CI vs OSCR Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, OSCR has a market cap of 7.1B. Regarding current trading prices, CI is priced at $295.72, while OSCR trades at $28.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas OSCR's P/E ratio is -50.41. In terms of profitability, CI's ROE is +0.15%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, CI is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check OSCR's competition here
CI vs ALHC Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, ALHC has a market cap of 4B. Regarding current trading prices, CI is priced at $295.72, while ALHC trades at $20.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas ALHC's P/E ratio is 192.00. In terms of profitability, CI's ROE is +0.15%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, CI is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check ALHC's competition here
CI vs CLOV Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, CLOV has a market cap of 2.2B. Regarding current trading prices, CI is priced at $295.72, while CLOV trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas CLOV's P/E ratio is -35.75. In terms of profitability, CI's ROE is +0.15%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, CI is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check CLOV's competition here
CI vs BHG Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, CI is priced at $295.72, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas BHG's P/E ratio is -0.12. In terms of profitability, CI's ROE is +0.15%, compared to BHG's ROE of -0.70%. Regarding short-term risk, CI is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BHG's competition here
CI vs CABR Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, CABR has a market cap of 18M. Regarding current trading prices, CI is priced at $295.72, while CABR trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas CABR's P/E ratio is -1.77. In terms of profitability, CI's ROE is +0.15%, compared to CABR's ROE of -3.00%. Regarding short-term risk, CI is more volatile compared to CABR. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check CABR's competition here
CI vs BMGL Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, BMGL has a market cap of 12M. Regarding current trading prices, CI is priced at $295.72, while BMGL trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas BMGL's P/E ratio is -1.45. In terms of profitability, CI's ROE is +0.15%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, CI is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for CI.Check BMGL's competition here
CI vs MRAI Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, MRAI has a market cap of 9.2M. Regarding current trading prices, CI is priced at $295.72, while MRAI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas MRAI's P/E ratio is -0.09. In terms of profitability, CI's ROE is +0.15%, compared to MRAI's ROE of +0.50%. Regarding short-term risk, CI is more volatile compared to MRAI. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MRAI's competition here
CI vs GTS Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, GTS has a market cap of 0. Regarding current trading prices, CI is priced at $295.72, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas GTS's P/E ratio is 10.41. In terms of profitability, CI's ROE is +0.15%, compared to GTS's ROE of +0.07%. Regarding short-term risk, CI is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check GTS's competition here
CI vs AET Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, AET has a market cap of 0. Regarding current trading prices, CI is priced at $295.72, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas AET's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to AET's ROE of +0.11%. Regarding short-term risk, CI is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check AET's competition here
CI vs MGLN Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, CI is priced at $295.72, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas MGLN's P/E ratio is 8.49. In terms of profitability, CI's ROE is +0.15%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, CI is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check MGLN's competition here
CI vs UAM Comparison June 2026
CI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CI stands at 78B. In comparison, UAM has a market cap of 0. Regarding current trading prices, CI is priced at $295.72, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CI currently has a P/E ratio of 2.59, whereas UAM's P/E ratio is N/A. In terms of profitability, CI's ROE is +0.15%, compared to UAM's ROE of +0.17%. Regarding short-term risk, CI is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for CI.Check UAM's competition here